
Xeris Biopharma Holdings, Inc.: dividend
Price
$16.70
November 16, 2026Market cap $3.1B
What Ploutos Investor adds for Xeris Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 27% since Nov 5, 2026, when the 10-Q these figures come from was filed ($13.08 then, $16.66 on Nov 13, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Xeris Biopharma pays no dividend
It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 12.0% in a year.
All dividend stocksThe full analysis
What do Xeris Biopharma's filings show?
The dividend is one part of Xeris Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Does XERS pay a dividend?
It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 12.0% in a year.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.